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R
heumatic heart disease (RHD) is the most common acquired cardiovascular disease among children and young adults. In 2015, there were an estimated 33.4 million prevalent clinical cases with 319 400 deaths and 10.5 million disability-adjusted lifeyears. 1 The global distribution of RHD is uneven and strongly associated with conditions of social deprivation. The highest age-standardized RHD death and prevalence rates are found in South Asia, Oceania, and Central Sub-Saharan African populations, 1 although the disease remains endemic in most low-and middleincome countries. 2 A recent multinational registry (the REMEDY study [Global Rheumatic Heart Disease Registry]) in low-and middle-income countries showed that most patients with RHD have advanced RHD (63.9%) and complications at the time of diagnosis. 3 However, RHD is a cumulative process, and opportunities exist for early intervention. Although the initial episode(s) of acute rheumatic fever (ARF)/RHD almost exclusively occur in childhood, RHD most commonly presents in adolescents and young adults. 4, 5 The latent period between ARF and clinically apparent RHD presents an opportunity for early intervention.
Screening echocardiography has emerged as a potentially powerful tool for early RHD detection. [6] [7] [8] RHD diagnosed through screening echocardiography has been termed latent RHD, and classified as borderline or definite. 9 In screening >15 000 school children in Uganda, our team has detected a 3% prevalence of latent RHD. 10, 11 These findings have been replicated in other parts of Africa, 12, 13 Asia, 14, 15 South and Central America, 8, 16 and the Oceania, [17] [18] [19] [20] uncovering a large population that may benefit from early detection.
The utility of screening echocardiography in RHD endemic populations hinges on 2 critical parameters: (1) the rate of RHD progression and (2) the ability of benzathine penicillin G (BPG) prophylaxis to improve outcome, a critical requirement of evaluating the suitability of any condition for screening. 21 Policy decisions on the role of screening for RHD have stalled because of the lack of high-quality data to guide management of latent RHD.
Natural history studies have the potential to estimate the rate of latent RHD progression. In addition, in the absence of a randomized controlled trial, natural history studies may provide information on the ability of penicillin to modify the disease course. There have been 8 previously published natural history studies of latent RHD. 8, [22] [23] [24] [25] [26] [27] [28] Three of these were published before the publication of standardized criteria for latent RHD diagnosis, 8, 23, 26 making them difficult to compare. The remaining 5 studies 22, 24, 25, 27, 28 report on relatively small cohorts, ranging from 25 to 55 children, limiting the power to detect features that predict progression or regression of disease.
We have studied the largest cohort of children with latent RHD to date, with the hypothesis that risk factors for unfavorable outcome can be found through study of natural history data. The included children are part of the Ugandan National RHD registry (The Registry), enrolled during previous research studies on RHD prevalence 10 and the use of handheld echocardiography, 11, 29, 30 and during RHD outreach and an epidemiological study (Uganda National RHD Registry Program, Uganda Heart Institute, unpublished data) in Uganda.
METHODS

Setting
This study took place in Uganda under the auspices of the Ugandan National RHD Registry (The Registry), which is institutional review board approved by Makerere University, Kampala, Uganda; Case Western Reserve University, Cleveland, OH; and Children's National Health System, Washington, DC. The Registry was established in 2010 to capture the burden of clinical RHD presenting to the Ugandan Heart Institute, the single
Clinical Perspective
What is New?
• Rheumatic heart disease (RHD) remains the most common cardiovascular disease among the world's youth.
• Echocardiographic screening provides a promising tool for early detection, but the natural history of screen-detected RHD (latent RHD) remains unclear.
• In this large series of patients, we show that children with borderline and definite RHD by echocardiographic screening are at substantial risk of progression, 9% and 26%, respectively, at a median follow-up of 2.6 years.
• Furthermore, we identify younger age at diagnosis and the presence of morphological mitral valve features at diagnosis as independent risk factors for unfavorable outcomes.
What Are the Clinical Implications?
• This study adds to the growing knowledge of latent RHD and the role of echocardiographic screening as a tool to reduce the global burden of RHD.
• Children with screen-detected RHD remain at substantial clinical risk.
• Children with moderate-to-severe RHD at screening should be considered for treatment as clinically diagnosed RHD. • Children with borderline or mild definite RHD at screening should, at a minimum, be maintained in close clinical follow-up.
• In addition, our data highlight the need for a randomized clinical trial in this population to determine the effect of penicillin prophylaxis on the clinical course of RHD.
tertiary cardiology center in Uganda, and to support children with latent RHD detected through school-based screening. In 2015, The Registry expanded to the North (Gulu) where children with latent RHD detected through school screening were added. The majority of children in this study come from 2 large cohorts: children screened as part of the 2011 epidemiological study in Kampala, the Ugandan capitol, and largest city 10 (previous 2-year outcomes of this cohort reported 22 ), and children screened as part of ongoing collaborative research and clinical outreach in Gulu (2013 to the present) 11, 30 ( Figure 1 ).
Participants
Any child with latent RHD (borderline or definite RHD according to the 2012 World Heart Federation [WHF] criteria 9 ) enrolled in The Registry and with at least 1 year of follow-up data was eligible for study participation. In addition, a 3-month effort was made to contact patients who had been lost to clinical followup (no follow-up in the last 6 months for definite RHD and no follow-up in the last 12 months for borderline RHD) and bring them back for regular clinical care and registry enrollment (if not previously enrolled). Written informed consent and assent (≥8 years) for this project was obtained from all children and families during registry enrollment.
Follow-Up Assessment
The Registry captures demographic, socioeconomic, and clinical information, including cardiovascular symptoms, physical examination, and medication prescription and adherence at enrollment. Historical data are captured when available, and prospective data are gathered at follow-up visits. Registry staff routinely contact patients who have lapsed from clinical follow-up, and if reached, the reason for absence is noted, including death. For this study, the following variables were abstracted from the first follow-up after screening: age, sex, registry site, and length of follow-up (days). For study purposes, prescription of every-28-day intramuscular BPG, left at the discretion of the treating provider (Ugandan cardiologist), was determined at the initial follow-up visit. Adherence was based on days of coverage (each injection providing 28 days of coverage) when possible, and when not possible, as a percentage of prescribed injections received.
Echocardiographic Reporting
Two pediatric cardiologists with expertise in RHD (A.B., C.S.) blindly re-reported on the original first postscreening followup echocardiograms to determine study eligibility. These studies and all follow-up studies were performed on a highend echocardiography machine (General Electric VIVID Q, or Philips iE33); results are stored on the Children's National Health System core echocardiography laboratory PACS system (Philips Xcelera). Diagnosis was made strictly according to the 2012 WHF criteria 9 and reported as definite RHD, borderline RHD, congenital or other acquired heart disease, or normal. Definite and borderline RHD were further classified into WHF subcategories (A-C borderline, A-D definite). Mitral and aortic regurgitation and mitral stenosis were classified as trivial (only regurgitation), mild, moderate, or severe according to published standards. 31, 32 Children with definite RHD were classified by severity of regurgitation at the most affected valve (mild, moderate, severe), or severe if any mitral stenosis was present at baseline. Children with nonspecific valvular abnormalities not meeting criteria for RHD by the 2012 WHF criteria 9 were excluded, because the outcomes for these children have been previously reported as benign. 22, 24 All available longitudinal echocardiograms (typically every 6 months in definite RHD and every 12 months in borderline RHD) were reinterpreted in series (A.B., C.S.). Serial reporting was chosen because it is the standard method in clinical practice to determine an individual's longitudinal outcome. Cases were assessed for echocardiographic progression or regression and the time to event (in days) was noted.
Echocardiographic progression was defined as follows:
• A worsening in diagnostic category (borderline to definite) • A worsening in the severity of regurgitation at the mitral or aortic valve (none or physiological, mild, moderate, severe) • Development of new mitral stenosis or an increase in grade of mitral stenosis (mild, moderate, severe) • Death attributable to the complication of RHD Echocardiographic regression was defined as follows:
• An improvement in diagnostic category (definite, borderline, normal) • An improvement in severity of regurgitation (severe, moderate, mild, physiological, none) Reasons for echocardiographic progression and regression were noted, and the time to the first echocardiogram noting change was recorded. Cases that did not meet these definitions for progression or regression were considered stable. If a child showed a nonlinear outcome (example: initial worsening and then return to baseline), the findings of the last available echocardiogram were used to determine the final outcome.
Because echocardiogram reviews in series were unblinded, 2 measures of agreement were undertaken to ensure that this procedure did not bias results. First, a subset of randomly selected echocardiograms was re-reviewed by a blinded outside cardiologist (M.M.) with expertise in the 2012 WHF criteria and in latent RHD to calculate interrater agreement. Second, a subset of final echocardiograms was re-reviewed blindly by the original readers to calculate intrareviewer agreement on final diagnosis.
Statistical Analysis
Propensity score and other bias-reducing analyses were implemented in Stata (Version 14); all other analyses were performed using SAS (Version 9.3). Descriptive statistics were used to summarize disease progression versus regression by overall category and subcategory. The Cohen κ statistic was used to evaluate the interrater agreement of diagnosis. Moderate and severe definite RHD, including all patients with mitral stenosis, were considered missed clinical RHD cases rather than true latent RHD. These missed clinical cases were excluded from risk factor analysis.
Borderline and mild definite RHD group were combined for risk factor analysis by using the Fisher exact test for categorical variables and the Wilcoxon-Mann-Whitney test for continuous, nonnormally distributed, variables. The outcome categories stable, progression, and regression were dichotomized in 2 ways in subsequent analyses (Table 1) . Outcome 1 compared progression versus the collapsed favorable outcomes stable or regression. The definition of outcome 2 varied by category of RHD. For mild definite cases, progression or stable was compared with regression (with the rationale that stable definite RHD has clinical significance). For borderline cases, progression was compared with the collapsed favorable outcome stable or regression (with the rationale that stable borderline RHD is of little immediate consequence). Bivariate logistic regression was used to identify individual risk factors for progression, and factors that were significant at P<0.10 were included as covariables in multivariable models. Kaplan-Meier curves and the log-rank test were used to compare the progression-free survival distributions of borderline and mild definite RHD.
Following logistic modeling, multivariable Cox proportional hazards modeling was conducted for outcome 1, adjusting for covariables, to determine risk factors for progression over the time period studied. To substantially reduce differences between the groups receiving and not receiving penicillin prophylaxis at baseline, propensity score-matched, and other forms of matched analysis, as well, were implemented. The other forms included regression-based adjustment for confounders, inverse probability weighting, and nearest-neighbor matching. Sensitivity analyses were conducted to evaluate the likely impact of uncontrolled differences between the groups receiving and not receiving penicillin.
RESULTS
Two hundred eighty-two cases of latent RHD (>1 year of follow-up) were identified in The Registry, with 1062 corresponding echocardiograms. On blinded re-review of the first follow-up echocardiograms (after screening), 50 were determined to be nonspecific valve disease not meeting the 2012 WHF criteria for RHD, 5 as other heart disease (4 mitral valve prolapse, 1 subaortic membrane), and 227 as latent RHD (63 definite RHD and 164 borderline RHD). Of those with definite RHD, 42 were classified as mild and 21 as moderate to severe (Figure 2) . Details of echocardiographic diagnosis at baseline are shown in Table 2 . Inter-and intrareviewer agreement based on the trinomial classification (normal/other, borderline, definite) was substantial (κ[inter]=0.72; 95% confidence interval [CI], 0.52-0.93; κ[intra]=0.78; 95% CI, 0.67-0.88). 33 The characteristics of the 227 children with confirmed latent RHD are detailed in Table 2 . Median age Of those prescribed penicillin, the overall adherence (≥80% days covered or ≥80% injection received) was quite good at 84.7%, with 89 children (82.4%) individually meeting the ≥80% benchmark. There were no cases of ARF captured in the registry during the followup period.
RHD Status
The outcomes of children with moderate and severe RHD were poor ( Figure 3 ). Of 21 children, only 2 (9.5%) showed echocardiographic regression during the study period. Of the other 19 children, 9 (42.9%) remained with moderate-to-severe RHD, 8 (38.1%) progressed, and 2 (9.5%) died during the follow-up period (Figure 2) . No child underwent a valve intervention during the study period. Among children with mild definite RHD (n=42), 11 (26.2%) children showed progression, 12 (28.6%) children remained stable, and 19 (45.2%) children showed echocardiographic regression. Penicillin was prescribed to 39 of 42 children with mild definite RHD (92.9%), and 27 of 39 (69.2%) had adherence ≥80%, reflecting effective prophylaxis in 64.3% of children with mild definite RHD (27/42). The most common reasons for progression included worsening of mitral regurgitation (54.5%) and worsening of aortic regurgitation (36.4%). The most common reasons for regression included improvement in mitral regurgitation (65.0%) and improvement of mitral valve morphology (35.0%). Full details on progression and regression are provided in Table 3 .
Among children with borderline RHD (n=164), 16 (9.8%) showed progression, 72 (43.9%) remained stable, and 76 (46.3%) showed echocardiographic regression. Penicillin was prescribed to 49 children (29.9%) with borderline RHD, and 44 (90%) had adherence ≥80%, reflecting effective prophylaxis in 26.8% of these children (44/164). The most common reasons for progression included worsening of mitral regurgitation (56.3%) and worsening of aortic regurgitation (36.4%). The most common reasons for regression included resolution of abnormal mitral valve morphological findings (35.0%) and improvement of mitral regurgitation (65.0%). The majority of initial progression occurred during the first 2 years of follow-up. Children with mild definite RHD were more likely to show progression than children with borderline RHD (P<0.01; Figure 4 ). Full details on progression and regression are provided in Table 3 .
There were 5 children who demonstrated a more complex pattern of change. Of these, 4 wavered between normal and borderline RHD based solely on small changes in mitral regurgitation jet length (above and below the 2-cm cutoff). In these cases, there was no clinically meaningful change, but only variation in diag- nostic category because of the strict application of the 2012 WHF criteria. In the final case, an initial echocardiogram showed definite RHD (thickened anterior mitral leaflet and excessive anterior mitral leaflet motion, and mild mitral regurgitation, as well). On the second echocardiogram, the excessive motion had resolved (then borderline because <2 morphological criteria were met), and then on echocardiograms 3 to 5, the posterior mitral leaflet became restricted. It is likely, in this child, that this pattern of change simply represents natural RHD progression.
Risk Factors
Because penicillin prophylaxis was prescribed to only one-third of children with borderline RHD, before undertaking risk factor analysis, we evaluated whether there were any echocardiographic or clinical differences between children with borderline RHD who were or were not initially prescribed prophylaxis. Length of mitral regurgitation was found to be associated with penicillin prescription (P=0.03), whereas year of diagnosis, subcategory of borderline RHD (A-C), presence of aortic insufficiency, and abnormal mitral valve morphology were not associated (respectively, P=0.19, 0.08, 0.65, and 0.72). Table 4 shows the results of the bivariate analysis for risk factors. In outcome 1, category of mild definite RHD, morphologically abnormal mitral or aortic valves, pathological aortic insufficiency, and penicillin prescription were more likely to progress. In outcome 2, the same risk factors emerged, except for the addition of mitral valve excessive anterior leaflet motion as an additional risk factor (Table 4) .
In a multivariable model, children who had pathological aortic insufficiency were more likely to progress (outcome 1) than those without (odds ratio [OR], 5.37; 95% CI, 1.54-18.69). In outcome 2, pathological aortic regurgitation remained an independent risk factor in addition to the mitral valve morphological features restricted leaflet motion and excessive anterior leaflet motion (OR, 6.09; 95% CI, 1.81-20.44; OR, 5.29; 95% CI, 1.22-22.92; and OR, 7.31; 95% CI, 1.13-46.94, respectively). Increasing age at diagnosis decreased the odds of progression in both models (OR, 0.83; 95% CI, 0.70-0.99 and OR, 0.84; 95% CI, 0.71-0.99) for every year increased age for outcome 1 and 2, respectively) ( Table 5) .
Results of Cox proportional hazards regression for outcome 1 were similar to those obtained by using logistic regression. Risk of progression over time was increased for children with pathological aortic insufficiency (hazard ratio, 5.69; 95% CI, 2.01-16.14), with hazard ratios for other risk factors similar to the previously reported ORs (data not shown).
After adjusting for differences in sex, age, presence of aortic regurgitation, and the presence and degree of mitral regurgitation, as well, penicillin prophylaxis in children with borderline RHD was associated with increased odds of progression (outcome 2: OR, 2.57; 95% CI, 0.81-8. 19 ). As indicated in Table 6 , propensity score-matched and other forms of analysis designed to remove confounding did not alter this result. These analyses produced results consistent with >2-fold increase in AR indicates aortic regurgitation; AV, aortic valve; BPG, benzathine penicillin G; IQR, interquartile range; MR, mitral regurgitation; MV, mitral valve; RHD, rheumatic heart disease; UHI, Uganda Heart Institute; and WHF, World Heart Federation.
the odds of progression (9%-10% absolute risk difference) in penicillin users. However, none of the results achieved better than borderline statistical significance (P=0.086 to P=0.098). In addition, sensitivity analysis strongly indicated that accounting for any uncontrolled confounding would likely lead to a further increase in the greater risk of progression associated with penicillin prophylaxis in participants affected by borderline RHD.
DISCUSSION
A significant knowledge gap remains surrounding natural history of latent RHD found by echocardiographic screening. Understanding the natural history of latent, echocardiography-detected RHD remains a critical component of evaluating the utility of more widespread implementation of echocardiographic screening programs. Here, we report the natural history of the largest longitudinal cohort of children with latent RHD to date looking specifically at risk factors for unfavorable outcomes. Four major findings emerge from our study.
First, not all screen-detected RHD should be considered latent RHD, because some children were found to have moderate-to-severe RHD on screening echocardiography, and they demonstrated poor outcomes. In our cohort, only 2 such children (9.5%) showed improvement over the study period, and there were 2 deaths (9.5%). Similar findings were recently reported from Fiji, where >80% of children with moderate-to-severe RHD at the time of screening showed persistence or progression. 24 When screening reveals moderateto-severe RHD, children should be considered missed clinical cases and treated as such, with referral to a specialist provider, consideration of BPG prescription, and valvular intervention as appropriate and available.
Second, children with mild definite RHD at the time of screening echocardiography show more progression than children with borderline RHD at screening. In our cohort, 25% of children with mild definite RHD showed progression in comparison with only 10% of those with borderline RHD. Progression is challenging to directly compare across cohorts, even in those using the 2012 WHF criteria, because of inconsistent definitions of progression, use of different binomial outcomes (stable + progression), and inclusion of children with advanced RHD. However, the ratio of progression among those with mild definite RHD in comparison with those with borderline in our cohort (2.5:1) is similar to reports from Fiji (2.5:1). 24 The progression seen among children with borderline RHD in our Values shown are n (%). AV indicates aortic valve; MV, mitral valve; and RHD, rheumatic heart disease.
*Some children showed >1 reason for progression or regression. †At least 2 morphological features at the mitral valve including thickened anterior mitral leaflet (≥3 mm), restricted leaflet motion, chordal thickening, excessive anterior mitral leaflet motion, or at least 2 morphological features at the aortic valve including thickening, prolapse, noncoaptation, or restricted motion.
‡Fewer than 2 morphological features of the mitral valve or aortic valve.
study (10%) is also similar to smaller recent cohorts from New Caledonia (5%) 28 and Fiji (12%), 24 although lower than reported from South Africa (20%) 27 and Australia (24%). 25 However, the category of RHD itself may not be as great a risk as specific echocardiographic features. Our third major finding was the identification of risk factors for unfavorable outcome based on a multiple-variable model. Although initial RHD category (borderline versus mild definite RHD) was a highly significant risk factor for unfavorable outcome in our bivariate model, it did not retain statistical significance in the multiple-variable model. For outcome 1 (progression versus stable + regression), only the presence of pathological aortic insufficiency emerged as a significant risk factor, whereas older age at diagnosis was protective from progression. In outcome 2 (mild definite RHD progression + stable versus regression or borderline RHD progression versus stable + regression), additional mitral morphological features including restrictive leaflet motion and excessive anterior leaflet motion were also risk factors.
There are 2 aspects of progression that are of primary interest in terms of prevention of sequelae: first evidence of (initial) progression and rate of progression over time. Our Kaplan-Meier analysis provided important evidence that initial echocardiographic progression may be detected during the first 2 years of clinical follow-up. There is also evidence that RHD progression may not be uniform. The rate of RHD progression is affected by the ongoing inflammatory response from the first insult and repeat insults in the form of repeated group A streptococcus exposure and ARF recurrences, providing reasons to suspect nonuniform progression. Data from clinical ARF and RHD are clear that progression of RHD continues over time. 34, 35 In our study, we are referencing only initial progression. Our data suggest that initial evidence of progression may emerge early in follow-up, which has implications for the use of secondary prophylaxis and for retention in care. Longer natural history studies are needed to determine whether early evidence of progression is, in fact, predictive of longer-term outcomes, including the need for future cardiac medications, interventions, and premature death, and whether these key indicators of progression occur at differential rates over time.
Length of follow-up did not emerge as a risk factor in our bivariate analysis. It may be that we were underpowered to find differences, but the previous report had similarly small numbers (19 children with ≥5 years follow-up 24 ) and was underpowered to conduct a multivariate analysis. It is also important to remember that, in our study, we are referencing only initial progression. Data from clinical ARF and RHD are clear that progression of RHD continues over time. 34, 35 However, our data suggest that disease trajectory may emerge early in follow-up, which has implications for the use of secondary prophylaxis and for retention in care. Longer natural history studies are needed to determine if early trajectory is, in fact, predictive of longer-term outcomes including the need for future cardiac medications, interventions, and premature death. Fourth, the impact of penicillin on improving the trajectory of latent RHD remains unclear. BPG prophylaxis emerged as a risk factor for progression, a finding also reported from Australia. 25 This result failed to reach statistical significance but persisted unabated despite extensive efforts, including propensity score matching with sensitivity analyses, to remove extraneous differences between penicillin-treated and untreated children. This counterintuitive finding has important implications for the prevention of sequelae in persons with latent disease and thus needs to be further investigated in a randomized clinical trial.
As more data emerge on the natural history of latent RHD, it is important to consider standardized reporting of outcomes. 36 The 2012 WHF criteria represent the best available evidence for the echocardiographic diagnosis and classification of latent RHD, and have been widely adopted facilitating reproducible diagnostic categories. 9 Defining latent RHD trajectory has been less uniform both in what constitutes change and in how trinomial outcomes are grouped into binomial classifications. Here, as reported by several recent studies, 24, 25 we use an expanded definition of change including but not limited to change in WHF category. Expert agreement on these definitions would facilitate better comparison across populations, but until this agreement, clear reporting of definitions and provision of granular details on reasons for change is essential. 36 Grouping of disease trajectory into clinically meaningful outcomes is also important. In this study we chose to report outcomes in 2 ways: first, with only progression versus stable and regression, and second, in the way we found most clinically relevant, grouping progression and stable definite RHD as the worse outcome, while considering only progression of borderline RHD as the worse of 2 outcomes. It is interesting to note that these groupings did not affect our multivariate analysis greatly, with only additional morphological features emerging in outcome 2.
When possible, it is also important to include multiple-variable analysis to determine which risk factors remain important. In our cohort, many seemingly key variables in bivariate analysis, including disease category and prescription of BPG prophylaxis, were not independent risk factors in our multivariate analysis. In part, this reflects the number of correlated confounders likely to surface in natural history studies. Because many longitudinal RHD cohorts remain small, combining data for a larger multicenter analysis remains a top priority.
Limitations
The main limitation in our study was the inability to determine the impact of BPG prophylaxis on the trajectory of latent RHD. This limitation is inherent to all natural history cohorts, reinforcing the need for a well-designed randomized controlled trial in this population. Based on our data, we would advocate the exclusion of children with moderate-to-severe definite RHD at the time of screening but believe that equipoise exists to justify inclusion of both mild definite and borderline RHD in such a trial. Similarly, we did not collect data on streptococcal exposure in this cohort and cannot determine the contribution of repeated group A streptococcus exposure to latent disease trajectory. A second limitation is the relatively small number of mild definite RHD cases included in our cohort (n=42). Although comparatively large relative to previous studies, 8, [22] [23] [24] [25] [26] [27] [28] this is still a small number of patients and may be underpowered to detect important risk factors for unfavorable outcome. Third, there is selection bias of our included cases: schoolgoing children at time of screening and only those who were enrolled in the national RHD registry. There are no data to suggest that children who do not attend school are at greater risk of latent RHD or of progression; however, this is possible considering the lower overall socioeconomic status in this group, a known driver of RHD. Fourth, significant changes in systemic blood pressure can change the appearance and grade of mitral and aortic regurgitation. We did not capture blood pressure at each echocardiogram; however, of 223 patients with data on age, height, and blood pressure at registry enrollment, 221 were normotensive, suggesting this is likely not a driver of change in disease categorization in our population. In addition, not all children with screen-detected RHD returned for initial follow-up and were enrolled in the national registry. We cannot determine if or how these losses affected our results. Finally, although initial echocardiograms were re-reviewed blindly for disease classification, we intentionally chose to review serial echocardiograms in an unblinded fashion (able to look forward and back within a case). This study is among the first to review and report on serial echocardiograms during the follow-up period (in comparison with only first and last), which has provided important information on timing of initial change. We also believe that side-by-side comparison strengthens the ability of a reviewer to see meaningful differences over time, as is standard clinical practice. In addition, we invited an expert cardiologist outside our group to review a randomly selected batch of echocardiograms, and found substantial agreement in category of diagnosis (normal/other, borderline, definite), indicating no significant bias was introduced through this method.
Conclusions
Latent RHD is a heterogeneous diagnosis with variable disease outcomes. Children with moderate-to-severe latent RHD found by echocardiographic screening should be considered missed clinical cases and treated as such, because their outcomes are poor. Children with both borderline and mild definite RHD are at substantial risk of progression, and at a minimum should be enrolled in close clinical follow-up. Although long-term outcomes remain unclear, the worsening of latent RHD may be evident through echocardiographic assessment during the first 1 to 2 years following diagnosis. Natural history data are inherently limited by confounding variables, and a randomized controlled clinical trial is needed to definitively determine the impact of BPG prophylaxis on the trajectory of latent RHD.
